S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
OPEC+ makes big oil cut to boost prices; pump costs may rise
Stocks slump as Wall Street’s big rally fades, yields rise
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
OPEC+ makes big oil cut to boost prices; pump costs may rise
Stocks slump as Wall Street’s big rally fades, yields rise
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
OPEC+ makes big oil cut to boost prices; pump costs may rise
Stocks slump as Wall Street’s big rally fades, yields rise
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
OPEC+ makes big oil cut to boost prices; pump costs may rise
Stocks slump as Wall Street’s big rally fades, yields rise
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
Hot Potato: Lamb Weston Stock Confirms a Top 
NASDAQ:AZN

AstraZeneca - AZN Stock Forecast, Price & News

$56.73
-0.31 (-0.54%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$55.99
$56.91
50-Day Range
$53.02
$68.26
52-Week Range
$52.65
$71.70
Volume
9.26 million shs
Average Volume
6.83 million shs
Market Capitalization
$175.80 billion
P/E Ratio
N/A
Dividend Yield
1.60%
Price Target
$62.00

AstraZeneca MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
15,483.5% Upside
$8,840.50 Price Target
Short Interest
Healthy
0.21% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.28mentions of AstraZeneca in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.48%
From $3.31 to $3.69 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

302nd out of 1,072 stocks

Pharmaceutical Preparations Industry

133rd out of 534 stocks

AZN stock logo

About AstraZeneca (NASDAQ:AZN) Stock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

Is Illumina Still the Gamechanger in Genomics Sequencing? (AZN)
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused
"The Most Critical Metal for Global Economies"
The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year.
"The Most Critical Metal for Global Economies"
The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year.
5 Dividend Growth Stocks to Beat Market Volatility
Form 6-K ASTRAZENECA PLC For: Sep 27 - StreetInsider.com
AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication
AstraZeneca (NASDAQ:AZN) Reaches New 1-Year Low at $53.34
AstraZeneca (NASDAQ:AZN) Sets New 52-Week Low at $53.34
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Company Calendar

Last Earnings
7/29/2022
Ex-Dividend for 9/12 Dividend
8/11/2022
Dividend Payable
9/12/2022
Today
10/05/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AZN
Employees
83,100
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$8,840.50
High Stock Price Forecast
$13,000.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+9.3%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$112 million
Pretax Margin
-4.17%

Debt

Sales & Book Value

Annual Sales
$37.42 billion
Cash Flow
$4.52 per share
Book Value
$12.68 per share

Miscellaneous

Outstanding Shares
3,098,840,000
Free Float
N/A
Market Cap
$175.80 billion
Optionable
Optionable
Beta
0.49

Social Links


Key Executives

  • Mr. Pascal Soriot D.V.M.Mr. Pascal Soriot D.V.M. (Age 63)
    M.B.A., CEO & Exec. Director
    Comp: $5.46M
  • Dr. Aradhana Sarin M.D.Dr. Aradhana Sarin M.D. (Age 47)
    CFO & Exec. Director
    Comp: $4.04M
  • Mr. Marc DunoyerMr. Marc Dunoyer (Age 70)
    CEO of Alexion & Chief Strategy Officer
    Comp: $1.91M
  • Ms. Pam P. ChengMs. Pam P. Cheng (Age 51)
    EVP of Operations & Information Technology and Member of External Sustainability Advisory Board
  • Mr. Chris Sheldon
    Head of Investor Relations
  • Mr. Jeffrey Pott
    Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board
  • Ms. Katarina AgeborgMs. Katarina Ageborg
    EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board
  • Gonzalo Vina
    Head of Global Media Relations
  • Dr. Menelas Pangalos Ph.D.Dr. Menelas Pangalos Ph.D. (Age 55)
    EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
  • Dr. Ruud Dobber Ph.D.
    Exec. Vice-Pres of BioPharmaceuticals Bus. Unit













AZN Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AZN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AZN, but not buy additional shares or sell existing shares.
View AZN analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price forecast for 2022?

13 equities research analysts have issued 1-year target prices for AstraZeneca's shares. Their AZN share price forecasts range from $54.00 to $13,000.00. On average, they expect the company's share price to reach $8,840.50 in the next twelve months. This suggests a possible upside of 15,483.5% from the stock's current price.
View analysts price targets for AZN
or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2022?

AstraZeneca's stock was trading at $58.25 at the start of the year. Since then, AZN stock has decreased by 2.6% and is now trading at $56.73.
View the best growth stocks for 2022 here
.

When is AstraZeneca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our AZN earnings forecast
.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) posted its earnings results on Friday, July, 29th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.78 by $0.08. The business had revenue of $10.77 billion for the quarter, compared to analyst estimates of $10.44 billion. AstraZeneca had a negative net margin of 2.84% and a positive trailing twelve-month return on equity of 25.88%.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semi-annual dividend on Monday, August 1st. Shareholders of record on Friday, August 12th will be paid a dividend of $0.465 per share on Monday, September 12th. This represents a dividend yield of 2.2%. The ex-dividend date is Thursday, August 11th.
Read our dividend analysis for AZN
.

Is AstraZeneca a good dividend stock?

AstraZeneca (NASDAQ:AZN) pays an annual dividend of $0.91 per share and currently has a dividend yield of 1.60%.
Read our dividend analysis for AZN.

When did AstraZeneca's stock split?

AstraZeneca's stock split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

2,350 employees have rated AstraZeneca Chief Executive Officer Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among the company's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. 87.0% of employees surveyed would recommend working at AstraZeneca to a friend.

What other stocks do shareholders of AstraZeneca own?
What is AstraZeneca's stock symbol?

AstraZeneca trades on the NASDAQ under the ticker symbol "AZN."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different retail and institutional investors. Top institutional investors include Park National Corp OH (0.00%), First Hawaiian Bank (0.00%), LVM Capital Management Ltd. MI (0.00%), Moody National Bank Trust Division (0.00%), Csenge Advisory Group (0.00%) and American National Bank (0.00%).
View institutional ownership trends
.

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $56.73.

How much money does AstraZeneca make?

AstraZeneca (NASDAQ:AZN) has a market capitalization of $175.80 billion and generates $37.42 billion in revenue each year. The company earns $112 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does AstraZeneca have?

The company employs 83,100 workers across the globe.

Does AstraZeneca have any subsidiaries?
The following companies are subsidiares of AstraZeneca: AAPM Sar, AZ Reinsurance Limited, AZ-Mont Insurance Company, AZENCO2 Limited, AZENCO4 Limited, Acerta Pharma B.V., Acerta Pharma LLC, AcertaPharma, Aktiebolaget Hassle, Alexion Pharmaceuticals, Almirall, AlphaCore Pharma, Amylin Ohio LLC, Amylin Pharmaceuticals LLC, Archigen Biotech Limited, Ardea Biosciences, Ardea Biosciences Limited, Arrow Therapeutics, Arrow Therapeutics Limited, Aspire Therapeutics B.V., Astra Alpha Produtos Farmaceuticos Lda, Astra Export & Trading Aktiebolag, Astra Lakemedel Aktiebolag, Astra Pharmaceuticals Limited, Astra Tech International Aktiebolag, AstraPharm, AstraZeneca (Israel) Ltd, AstraZeneca (Thailand) Limited, AstraZeneca (Wuxi) Trading Co. Ltd, AstraZeneca A/S, AstraZeneca AB, AstraZeneca AG, AstraZeneca AS, AstraZeneca Asia-Pacific Business Services Sdn Bhd, AstraZeneca B.V., AstraZeneca BioVentureHub AB, AstraZeneca Biotech AB, AstraZeneca Bulgaria EOOD, AstraZeneca CAMCAR Costa Rica S.A., AstraZeneca CAMCAR S.A., AstraZeneca Canada Inc., AstraZeneca China UK Limited, AstraZeneca Collaboration Ventures LLC, AstraZeneca Colombia S.A.S., AstraZeneca Continent B.V., AstraZeneca Czech Republic s.r.o., AstraZeneca Death In Service, AstraZeneca Dunkerque Production SCS, AstraZeneca Eesti OÜ, AstraZeneca Egypt for Pharmaceutical Industries JSC, AstraZeneca Egypt for Trading LLC, AstraZeneca Employee Share Trust Limited, AstraZeneca FZ-LLC, AstraZeneca Farmaceutica Chile Limitada, AstraZeneca Farmaceutica Holding Spain S.A., AstraZeneca Farmaceutica Spain S.A., AstraZeneca Finance Limited, AstraZeneca Finance S.A.S., AstraZeneca Gamma B.V., AstraZeneca GmbH, AstraZeneca Health Care Division S.A. de C.V., AstraZeneca Holding Aktiebolag, AstraZeneca Holding France S.A.S., AstraZeneca Holding GmbH, AstraZeneca Holdings B.V., AstraZeneca Holdings Pty Limited, AstraZeneca Hong Kong Limited, AstraZeneca Ilac Sanayi ve Ticaret Limited Sirketi, AstraZeneca India Private Limited, AstraZeneca Industries LLC, AstraZeneca Intermediate Holdings Limited, AstraZeneca International Holdings Aktiebolag, AstraZeneca Investment (China) Co. Ltd, AstraZeneca Investments Limited, AstraZeneca Japan Limited, AstraZeneca Jota B.V., AstraZeneca K.K., AstraZeneca Kft, AstraZeneca Korea Co. Ltd, AstraZeneca Latvija SIA, AstraZeneca Lietuva UAB, AstraZeneca Limited, AstraZeneca Luxembourg S.A., AstraZeneca Maroc SARLAU, AstraZeneca Nigeria Limited, AstraZeneca Nominees Limited, AstraZeneca Nordic AB, AstraZeneca OY., AstraZeneca PTY Limited, AstraZeneca Pars Company, AstraZeneca Peru S.A., AstraZeneca Pharma India Limited, AstraZeneca Pharma Poland Sp.z.o.o., AstraZeneca Pharma S.R.L., AstraZeneca Pharmaceutical (China) Co. Ltd, AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company, AstraZeneca Pharmaceuticals (Phils.) Inc., AstraZeneca Pharmaceuticals (Pty) Limited, AstraZeneca Pharmaceuticals Aktiebolag, AstraZeneca Pharmaceuticals Co. Limited, AstraZeneca Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, AstraZeneca Pharmaceuticals Limited, AstraZeneca Pharmaceuticals Pakistan (Private) Limited, AstraZeneca Pharmaceuticals Technologies (Beijing) Co. Ltd, AstraZeneca Produtos Farmaceuticos Lda, AstraZeneca Quest Limited, AstraZeneca Rho B.V., AstraZeneca S.A., AstraZeneca S.A. / N.V., AstraZeneca S.A. de C.V., AstraZeneca S.A.S., AstraZeneca Sdn Bhd, AstraZeneca Share Trust Limited, AstraZeneca Sigma B.V., AstraZeneca Singapore Pte Limited, AstraZeneca SpA, AstraZeneca Sweden Investments Limited, AstraZeneca Södertälje 2 AB, AstraZeneca Taiwan Limited, AstraZeneca Treasury B.V., AstraZeneca Treasury Limited, AstraZeneca Tunisie SaRL, AstraZeneca UK Limited, AstraZeneca US Investments Limited, AstraZeneca Ukraina LLC, AstraZeneca Venezuela S.A., AstraZeneca Vietnam Company Limited, AstraZeneca Zeta B.V, AstraZeneca d.o.o, AstraZeneca do Brasil Limitada, AstraZeneca Österreich GmbH, Atkemix Nine Inc., Atkemix Ten Inc., BMS Holdco Inc., Cambridge Antibody Technology, Cambridge Antibody Technology Group Limited, Centus Biotherapeutics Limited, Corpus Christi Holdings Inc., Definiens GmbH, Definiens Inc., Drimex LLC, Gotland Pharma S.A., Guangdong BeiKang Pharmaceutical Company Ltd, IPR Pharmaceuticals Inc., KuDOS Horsham Limited, KuDOS Pharmaceuticals Limited, KuDOS Pharmaceuticals Ltd, Laboratorio Beta S.A., Laboratorio Lailan S.A., Laboratorio Odin S.A., Laboratorio Tau S.A., MedImmune LLC, MedImmune Limited, MedImmune Pharma B.V, MedImmune U.K. Limited, MedImmune Ventures Inc, Montrose Chemical Corporation of California, Novastra Promoção e Comércio Farmacêutico Lda, Novastuart Produtos Farmaceuticos Lda, Novexel, Omthera Pharmaceuticals, Omthera Pharmaceuticals Inc., Optein Inc., P.T. AstraZeneca Indonesia, Pearl Therapeutics, Pearl Therapeutics Inc, Pharmaceutical Manufacturing Company Pty Limited, Pharmaceutical Manufacturing Division Pty Limited, SPA AstraZeneca Al Djazair, Simesa SpA, Sofotec GmbH, Spirogen Sarl, Stauffer Management Company LLC, Stuart Pharma Aktiebolag, Stuart-Produtos Farmacêuticos Lda, Symbicom Aktiebolag, Takeda Respiratory Business, Tika Lakemedel Aktiebolag, Trustee Limited, Unipessoal Lda, WuXi MedImmune Biopharmaceutical Co, ZS Pharma, ZS Pharma Inc, Zenco (No. 8) Limited, Zeneca Epsilon – Produtos Farmacêuticos Lda, Zeneca Finance (Netherlands) Company, Zeneca Holdings Inc., Zeneca Ilac Sanayi Ve Ticaret Anonim Sirketi, Zeneca Inc., Zeneca Wilmington Inc., and Zenecapharma Produtos Farmaceuticos .
Read More
How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The official website for the company is www.astrazeneca.com. The company can be reached via phone at 442037495000, via email at ir@astrazeneca.com, or via fax at 44-12-2335-2858.

This page (NASDAQ:AZN) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.